News GSK preps filings for chronic hepatitis B drug bepirovirsen GSK will file its chronic hepatitis B virus therapy bepirovirsen for approval in the first quarter, after it hit the mark in two phase 3 trials.
News Amgen inks $840m takeover of UK's Dark Blue Therapeutics Amgen has added a new acute myeloid leukaemia drug with the takeover of Dark Blue Therapeutics and its first-in-class MLLT 1/3 degrader.
News Lilly taps Nimbus for another obesity candidate For a second time, Eli Lilly has turned to Boston biotech Nimbus Therapeutics to add a potential weight loss therapy to its pipeline.
News Alumis shoots up as its Sotyktu rival aces psoriasis trials Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after two positive phase 3 trials.
News RNA specialist Ribo files $205m IPO in Hong Kong Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.
News CDC cuts recommended childhood jabs from 17 to 11 The CDC has upended the childhood vaccination schedule, cutting the number of recommended shots in a move that has dismayed medical organisations.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.